ATLANTA--(BUSINESS WIRE)--Please replace the release dated July 7, 2016 with the following corrected version due to multiple revisions.
The corrected release reads:
CSI LABORATORIES NOW OFFERING PD-L1 EXPRESSION ASSAY USED IN CONJUNCTION WITH MULTIPLE IMMUNOTHERAPIES
CSI Laboratories, a private national reference laboratory specializing in cancer diagnostics, announced today the availability of a PD-L1 (programmed death-ligand 1) immunohistochemical (IHC) protein expression assay. CSI’s PD-L1 immunohistochemical assay can be used to potentially predict a patient’s response to several commercially available PD-1/PD-L1 inhibitor therapies.1 CSI’s PD-L1 IHC assay provides a specimen’s PD-L1 tumor cell reactivity score which can be used to identify patients who are more likely to respond to certain PD-1/PD-L1 inhibitor therapies.
About CSI Laboratories
CSI Laboratories is a specialized cancer diagnostic laboratory focused specifically on meeting the unique needs and challenges of pathologists and community hospitals. The company provides diagnostic testing in flow cytometry, cytogenetic analysis, fluorescence in-situ hybridization (FISH), immunohistochemistry, molecular genetics, and consultations in the areas of hematopathology and surgical pathology. CSI Laboratories is a CLIA-certified and CAP-accredited laboratory located in Alpharetta, GA. CSI Laboratories is independently owned and operated by medical professionals, and has provided expert diagnostic testing to pathologists across the United States since 1997. For more information, please visit www.csilaboratories.com.
1 References Hansen AR, Siu LL. PD-L1 Testing in Cancer: Challenges in companion diagnostic development. JAMA Oncol.2016;2(1):15-16.
